2018
Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient
Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, Mulligan DC, Yoo PS. Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. Transplant Infectious Disease 2018, 20: e12966. PMID: 30014622, DOI: 10.1111/tid.12966.Peer-Reviewed Case Reports and Technical NotesConceptsHuman herpesvirus 8 infectionHepatic Kaposi sarcomaKaposi's sarcomaTransplant recipientsAdult liver transplant recipientsRegression of KSSplit liver transplantAcute cellular rejectionLiver transplant recipientsSuccessful therapeutic strategiesAllograft functionCellular rejectionLiver transplantSeropositive donorsSuccessful treatmentLiposomal doxorubicinTherapeutic strategiesRecipientsSarcomaInfectionTreatmentImmunosuppressionPatientsMalignancyTransplant
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response